BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22896677)

  • 21. Does smoking reduce the risk of Parkinson's disease through stimulation of the ubiquitin-proteasome system?
    Chapman MA
    Med Hypotheses; 2009 Dec; 73(6):887-91. PubMed ID: 19540050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteasomal dysfunction: a common feature of neurodegenerative diseases? Implications for the environmental origins of neurodegeneration.
    Halliwell B
    Antioxid Redox Signal; 2006; 8(11-12):2007-19. PubMed ID: 17034346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CSPα knockout causes neurodegeneration by impairing SNAP-25 function.
    Sharma M; Burré J; Bronk P; Zhang Y; Xu W; Südhof TC
    EMBO J; 2012 Feb; 31(4):829-41. PubMed ID: 22187053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome.
    Emmanouilidou E; Stefanis L; Vekrellis K
    Neurobiol Aging; 2010 Jun; 31(6):953-68. PubMed ID: 18715677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation.
    Freeman W; Morton AJ
    Brain Res Bull; 2004 Mar; 63(1):45-55. PubMed ID: 15121238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. K63-linked ubiquitination and neurodegeneration.
    Lim KL; Lim GG
    Neurobiol Dis; 2011 Jul; 43(1):9-16. PubMed ID: 20696248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interplay between 20S proteasomes and prion proteins in scrapie disease.
    Amici M; Cecarini V; Cuccioloni M; Angeletti M; Barocci S; Rossi G; Fioretti E; Keller JN; Eleuteri AM
    J Neurosci Res; 2010 Jan; 88(1):191-201. PubMed ID: 19658198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does impairment of the ubiquitin-proteasome system or the autophagy-lysosome pathway predispose individuals to neurodegenerative disorders such as Parkinson's disease?
    Matsuda N; Tanaka K
    J Alzheimers Dis; 2010; 19(1):1-9. PubMed ID: 20061621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+1.
    Hol EM; van Leeuwen FW; Fischer DF
    Trends Mol Med; 2005 Nov; 11(11):488-95. PubMed ID: 16213790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2).
    Rockwell P; Yuan H; Magnusson R; Figueiredo-Pereira ME
    Arch Biochem Biophys; 2000 Feb; 374(2):325-33. PubMed ID: 10666314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amyloid peptides in different assembly states and related effects on isolated and cellular proteasomes.
    Cecarini V; Bonfili L; Amici M; Angeletti M; Keller JN; Eleuteri AM
    Brain Res; 2008 May; 1209():8-18. PubMed ID: 18400214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease.
    Ohyagi Y; Asahara H; Chui DH; Tsuruta Y; Sakae N; Miyoshi K; Yamada T; Kikuchi H; Taniwaki T; Murai H; Ikezoe K; Furuya H; Kawarabayashi T; Shoji M; Checler F; Iwaki T; Makifuchi T; Takeda K; Kira J; Tabira T
    FASEB J; 2005 Feb; 19(2):255-7. PubMed ID: 15548589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target.
    Bett JS; Goellner GM; Woodman B; Pratt G; Rechsteiner M; Bates GP
    Hum Mol Genet; 2006 Jan; 15(1):33-44. PubMed ID: 16311253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does autophagy worsen or improve the survival of dopaminergic neurons?
    Pasquali L; Ruggieri S; Murri L; Paparelli A; Fornai F
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S24-7. PubMed ID: 20123552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of CSPα clients reveals a role in dynamin 1 regulation.
    Zhang YQ; Henderson MX; Colangelo CM; Ginsberg SD; Bruce C; Wu T; Chandra SS
    Neuron; 2012 Apr; 74(1):136-50. PubMed ID: 22500636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chaperoning the SNAREs: a role in preventing neurodegeneration?
    Burgoyne RD; Morgan A
    Nat Cell Biol; 2011 Jan; 13(1):8-9. PubMed ID: 21173802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cysteine string protein (CSP) and its role in preventing neurodegeneration.
    Burgoyne RD; Morgan A
    Semin Cell Dev Biol; 2015 Apr; 40():153-9. PubMed ID: 25800794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of the proteasome in fly models of neurodegeneration.
    Yeh CH; Jansen M; Schmidt-Glenewinkel T
    Methods Mol Biol; 2011; 793():149-65. PubMed ID: 21913099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurons Export Extracellular Vesicles Enriched in Cysteine String Protein and Misfolded Protein Cargo.
    Deng J; Koutras C; Donnelier J; Alshehri M; Fotouhi M; Girard M; Casha S; McPherson PS; Robbins SM; Braun JEA
    Sci Rep; 2017 Apr; 7(1):956. PubMed ID: 28424476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced expression of the presynaptic co-chaperone cysteine string protein alpha (CSPα) does not exacerbate experimentally-induced ME7 prion disease.
    Davies MJ; Cooper M; Perry VH; O'Connor V
    Neurosci Lett; 2015 Mar; 589():138-43. PubMed ID: 25623034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.